Serine Proteinases (3.4.21) (e.g., Trypsin, Chymotrypsin, Plasmin, Thrombin, Elastase, Kallikrein, Fibrinolysin, Streptokinease, Etc.) Patents (Class 424/94.64)
-
Publication number: 20140212405Abstract: A method is disclosed to dissolve protein deposited in muscle. The method includes the step of administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic agents.Type: ApplicationFiled: January 28, 2013Publication date: July 31, 2014Inventor: Blair Lamb
-
Publication number: 20140212385Abstract: Polypeptide having activity inducing pathogen plant defence, nucleotide sequence encodes it, microorganism, compositions and methods. The polypeptide is a subtilisin derived from a strain of Acremonium strictum. The polypeptide is encoded by the nucleotide sequence SEQ ID No.: 1 or sequences at least 90% homologous to the same and has the amino acid sequence SEQ ID No: 2 or sequences at least 90% homologous to the same.Type: ApplicationFiled: March 16, 2012Publication date: July 31, 2014Applicant: CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET)Inventors: Atilio Pedro Castagnaro, Juan Carlos Diaz Ricci, Nadia Regina Chalfoun, Josefina Racedo, Sergio Miguel Salazar
-
Publication number: 20140212406Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.Type: ApplicationFiled: September 7, 2012Publication date: July 31, 2014Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Denis Viven, Jerome Parcq
-
Patent number: 8791233Abstract: The present invention provides maspin-related compositions and methods of use thereof. In particular, the present invention provides maspin-related compositions, and methods or use thereof, for the promotion of cell adhesion.Type: GrantFiled: May 23, 2012Date of Patent: July 29, 2014Assignee: Northwestern UniversityInventor: Ming Zhang
-
Publication number: 20140205636Abstract: The invention relates to tissue adhesives or sealants, more specifically to fibrinogen based sealants reinforced with particulate material and chemically cross-linked. More particularly, the present invention is directed to tissue sealant, adhesive, hemostat, or scaffolding material containing thrombin, fibrinogen, a biocompatible particulate material having amine functionality, and a biocompatible polymer containing aldehyde groups. The present invention is also directed to methods for the use of such materials.Type: ApplicationFiled: January 24, 2013Publication date: July 24, 2014Applicant: ETHICON, INC.Inventor: Chetan Anirudh Khatri
-
Publication number: 20140205578Abstract: Described herein are methods for increasing insulin sensitivity and for treating Diabetes (Type I and Type II). Also described herein are methods for increasing the amount of brown fat in a subject and for treating metabolic disorders, including obesity.Type: ApplicationFiled: June 15, 2012Publication date: July 24, 2014Applicant: The John Hopkins UniversityInventors: Jonathan D. Powell, Bo Xiao, Paul Worley, Gregg M. Delgoffe, Adam Waickman
-
Publication number: 20140205588Abstract: The invention relates to variants of plasminogen and plasmin comprising one or more point mutations in the catalytic domain which reduce or prevent autocatalytic destruction of the protease activity of plasmin. Compositions, uses and methods of using said variants of plasminogen and plasmin are also disclosed.Type: ApplicationFiled: August 13, 2012Publication date: July 24, 2014Applicant: THROMBOGENICS NVInventor: Richard Reinier Zwaal
-
Publication number: 20140205587Abstract: Gluten-degrading proteases can be used to degrade gluten and for making gluten-containing food safer for patients suffering from gluten intolerance.Type: ApplicationFiled: June 13, 2012Publication date: July 24, 2014Applicant: ALVINE PHARMACEUTICALS, INC.Inventor: Matthew John Siegel
-
Publication number: 20140199287Abstract: The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire Desmodus rotundus (DSPA), for therapeutic treatment of stroke in humans. The invention provides a novel therapeutic base for treating stroke in humans.Type: ApplicationFiled: January 9, 2014Publication date: July 17, 2014Applicant: H. LUNDBECK A/SInventors: Mariola SOHNGEN, Wolfgang SOHNGEN, Wolf-Dieter SCHLEUNING, Robert MEDCALF
-
Patent number: 8771684Abstract: A method of alleviating pain associated with tissue damage includes applying salmon thrombin at a tissue damage site, as a single substance in liquid form, or as a powder, a foam, and/or a gel that includes salmon thrombin. A pain relief substance includes a salmon thrombin preparation.Type: GrantFiled: August 12, 2011Date of Patent: July 8, 2014Assignee: Sea Run Holdings, Inc.Inventors: Evelyn S. Sawyer, Paul A. Janmey, Beth A. Winkelstein
-
Publication number: 20140186328Abstract: The present invention provides neuroprotective polyphenol compounds, which can be synthetic analogs of fisetin, baicalein or chlorogenic acid, that maintain neuroprotective, anti-inflammatory, glutathione promoting, and/or antioxidant properties. The neuroprotective polyphenol compounds are useful for promoting, enhancing and/or increasing neuron protection, growth and/or regeneration. The polyphenol compounds further find use for increasing and or maintaining intracellular glutathione (GSH) levels. The polyphenol compounds are also useful for treating, preventing, mitigating and/or delaying neurodegenerative conditions, including diabetes, Parkinson's disease, Huntington's disease, Alzheimer's disease, non-Alzheimer's dementias, multiple sclerosis, traumatic brain injury, spinal cord injury or ALS.Type: ApplicationFiled: February 5, 2014Publication date: July 3, 2014Applicant: Salk Institute for Biological StudiesInventors: David R. Schubert, Pamela A. Maher, Chandramouli Chiruta
-
Publication number: 20140186329Abstract: The present invention provides methods of use of polyphenol compounds for treating, preventing, mitigating and delaying ischemia or a condition where ischemia occurs. In one embodiment, the method comprises providing a polyphenol analog; and administering the polyphenol analog to a subject to treat ischemia or a condition where ischemia occurs. Various embodiments of the present invention are useful for the treatment of patients having, or at risk for, any of (1) ischemic stroke, (2) hemorrhagic stroke, (3) cardiovascular disease, (4) ischemia related spinal cord injury, (5) ischemia in diabetic patients, or (6) embolic stroke. For example, use of the polyphenol compounds can maintain glutathione levels in the patient.Type: ApplicationFiled: February 6, 2014Publication date: July 3, 2014Inventors: Paul A. Lapchak, David R. Schubert, Pamela A. Maher, Chandramouli Chiruta
-
Publication number: 20140186327Abstract: The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.Type: ApplicationFiled: December 18, 2013Publication date: July 3, 2014Applicant: Amunix Operating Inc.Inventors: Volker Schellenberger, Joshua Silverman, Willem Peter Stemmer, Chia-wei Wang, Benjamin Spink, Nathan Carl Geething, Wayne To
-
Publication number: 20140186423Abstract: The present invention relates to a method and device for treating patients with a Protein Misfolding Disease by chronically administering an effective dose of a thrombolytic reagent and/or a thrombolytic reagent regulator over an intermittent period of time. The thrombolytic reagents degrade the misfolded proteins that accumulate and that can become toxic in such patients. The thrombolytic reagent regulators increase the catalytic efficiency of the thrombolytic reagents to reduce the amount of thrombolytic reagents necessary for an effective dose. The administration is administered transdermally via a transdermal patch that is equipped with an ultrasound transducer for enhancing the penetration of the thrombolytic reagent and thrombolytic reagent regulator into the bloodstream of a patient by increasing the permeability of the patient's skin.Type: ApplicationFiled: December 26, 2013Publication date: July 3, 2014Inventor: Mathew Gelfand
-
Publication number: 20140178356Abstract: The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.Type: ApplicationFiled: February 21, 2014Publication date: June 26, 2014Applicant: Novo Nordisk HealthCare AGInventors: Michael Bech Jensen, Birthe Lykkegaard Hansen, Troels Kornfelt
-
Patent number: 8754045Abstract: Compositions and methods are provided to destroy internal cancerous lesions selectively by the administration of a combination of a debridement protease enzyme and a denaturant of cell structural proteins and or cell adhesion proteins.Type: GrantFiled: May 14, 2007Date of Patent: June 17, 2014Inventor: James A. Livingston
-
Publication number: 20140161738Abstract: The invention discloses a pharmaceutical hemostatic liquid foam base preparation comprising albumin as foaming agent and a fibrinogen precipitating substance and optionally a coagulation inducing agent, wherein albumin as foaming agent is present in native form; a method for the production of a transient hemostatic liquid foam; the transient hemostatic liquid foam; and a kit for making the foam.Type: ApplicationFiled: December 6, 2013Publication date: June 12, 2014Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Andreas Goessl, Katarzyna Gorna
-
Publication number: 20140161787Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.Type: ApplicationFiled: June 25, 2013Publication date: June 12, 2014Applicant: CUREMARK LLCInventor: Joan M. Fallon
-
Patent number: 8747842Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.Type: GrantFiled: April 29, 2011Date of Patent: June 10, 2014Assignee: ThromboGenics NVInventors: Steve Pakola, Marc De Smet
-
Publication number: 20140154236Abstract: Described here are devices and methods for treating one or more conditions or symptoms associated with a tonsil procedure. In some variations, a drug-releasing device may be at least partially delivered to one or more tonsillar tissues before, during, or after a tonsil procedure. In some variations, the drug-releasing device may be configured to be biodegradable. In other variations, the drug-releasing device may comprise one or more hemostatic materials or one or more adhesives. The drug-releasing device may be configured to release one or more drugs or agents, such as, for example, one or more analgesics, local anesthetics, vasoconstrictors, antibiotics, combinations thereof and the like.Type: ApplicationFiled: February 6, 2014Publication date: June 5, 2014Applicant: INTERSECT ENT, INC.Inventors: Jerome E. HESTER, Anthony J. ABBATE, Richard E. KAUFMAN, David C. GALE, Gail M. ZALER, Bin HUANG, Lisa EARNHARDT, Vijaykumar RAJASEKHAR
-
Publication number: 20140154233Abstract: The present invention relates generally to a method of reducing the level of plasminogen and/or tissue plasminogen activator and/or other protease(s) in a solution comprising fibrinogen and/or Factor VIII and/or von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising fibrinogen and/or Factor VIII and/or VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that the plasminogen and/or tissue plasminogen activator and/or other protease(s) is bound to the resin; and (ii) recovering the solution comprising fibrinogen and/or Factor VIII and/or VWF which passes through the resin; wherein the concentration of the plasminogen and/or tissue plasminogen activator and/or protease(s) in the recovered solution is reduced by at least 50% compared to the feedstock. Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or Factor VIII and/or VWF recovered by such methods, and uses thereof.Type: ApplicationFiled: March 14, 2013Publication date: June 5, 2014Applicant: CSL LIMITEDInventors: Hung PHAM, Jeffrey Michael HEY, Darren NGUY
-
Publication number: 20140154235Abstract: Wound debridement compositions containing the proteolytic enzyme Seaprose and use of such compositions in wound treatment for the enzymatic debridement of wounds.Type: ApplicationFiled: May 11, 2012Publication date: June 5, 2014Applicant: SMITH & NEPHEW ORTHOPAEDICS AGInventors: Lei Shi, Aleksa Jovanovic, Dennis Carson
-
Publication number: 20140154234Abstract: Methods of generating thrombin and methods of applying a clotting tissue sealant to a site on a subject are provided. A blood component comprising platelets can be obtained from the subject. A hypotonic composition is contacted with a solid matrix to form a thrombin-containing liquid, where the hypotonic composition includes water, calcium, a blood component comprising platelets, and optionally a chelator. Calcium is present in the hypotonic composition in an amount greater than the amount of calcium that can be complexed by the chelator. Thrombin-containing liquid is then separated from the hypotonic composition and can be applied to the site on the subject to form a clot, for example, by combination with fibrinogen.Type: ApplicationFiled: October 25, 2013Publication date: June 5, 2014Applicant: Biomet Biologics, LLCInventors: Randel Dorian, Richard W. Storrs, Michael D. Leach
-
Patent number: 8741285Abstract: Intra-arterial administering at least one blood coagulation to a bleeding patient is provided, together with a pharmaceutical composition therefor.Type: GrantFiled: June 4, 2010Date of Patent: June 3, 2014Inventors: Dietmar Fries, Michael Rieger
-
Patent number: 8741286Abstract: The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders.Type: GrantFiled: June 4, 2013Date of Patent: June 3, 2014Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Olivier Christophe, Cecile Denis, Ghislaine Cherel, Paul Gueguen
-
Publication number: 20140147432Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.Type: ApplicationFiled: December 13, 2013Publication date: May 29, 2014Applicant: MODERNA THERAPEUTICS, INC.Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Susan Whoriskey, Sayda M. Elbashir
-
Publication number: 20140140979Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.Type: ApplicationFiled: January 18, 2013Publication date: May 22, 2014Applicant: Biosuccess Biotech Co. Ltd.Inventors: Zheng Tao Han, Hung-Fong Chen
-
Publication number: 20140140987Abstract: A method of introducing healthy good human cells to eat up bad damaged cells, comprising administering an effective amount of a healthy good protein containing transferrin, alpha 1-antitrypsin, apolipoprotein A and human albumin. The method further comprises administering an effective amount of a protein containing ApoA1/2/4, or administering an effective amount of a protein containing Factor II, Factor VII, Factor IX and Factor X in prothrombin complex concentrate. The method can further comprise administering an effective amount of fibrinogen, Factor VIII, high concentrate fibrinogen, thrombin. hepatitis B immune globulin (HBIG), anti-thrombin III (AT-III), protein C, fibronectin, protein S and protein M.Type: ApplicationFiled: October 17, 2013Publication date: May 22, 2014Inventor: Kieu Hoang
-
Publication number: 20140141065Abstract: Materials and methods for treating a patient to express a therapeutic agent comprising administering a Kupffer cell-suppressing substance in combination with a vehicle for introducing, into the patient, an exogenous nucleic acid comprising a sequence for expression of the agent.Type: ApplicationFiled: November 19, 2013Publication date: May 22, 2014Inventors: R. Scott McIvor, Perry B. Hackett, Jason Bell, Myra Christine Urness-Rusten, Elena Aronovich, David W. Hunter
-
Publication number: 20140134151Abstract: The present invention relates to antidotes of anticoagulants targeting factor Xa which antidotes are used in combination with blood coagulating agents or other heparin antidotes to prevent or reduce bleeding in a subject. The antidotes described herein have reduced or no intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is or will be undergoing anticoagulant therapy with a factor Xa inhibitor.Type: ApplicationFiled: April 30, 2013Publication date: May 15, 2014Applicant: Portola Pharmaceuticals, Inc.Inventors: Genmin Lu, Uma Sinha
-
Publication number: 20140135945Abstract: A growth factor delivery scaffold combines a heparin/fibrin-based delivery system (HBDS) with a backbone based on polymer nanofibers for tissue (e.g., tendon and ligament) repair. The scaffold has improved surgical handling properties compared to the gelatinous consistency of the prior art HBDS system and retains the capability for delivering mesenchymal cells and controlling the release of growth factors. One application for the scaffold is mesenchymal stem cell (MSC) therapy for flexor tendon repair. The scaffold can deliver growth factors in a sustained manner, can be implanted for flexor tendon repair, is biocompatible, and is not cytotoxic. The growth factor delivery scaffold may also be used in the surgical repair of an injury to bone, muscle, cartilage, or other tissues.Type: ApplicationFiled: January 17, 2014Publication date: May 15, 2014Inventors: Stavros Thomopoulos, Shelly Sakiyama-Elbert, Matthew Silva, Richard Gelberman, Younan Xia, Andrea Schwartz, Jingwei Xie
-
Publication number: 20140134152Abstract: Embodiments of the present invention relate to compositions and methods of treating patients for type 1 diabetes mellitus (T1D) by administering a therapeutically effective dose of recombinant human KLK1, variants of KLK1, or active fragments thereof. Such patients may be increase risk patients for developing T1D or T1D patients in the Honeymoon Phase. Such treatment may be expected to prevent or delay the onset of T1D, to ameliorate the symptoms of T1D, or to ameliorate the extent to which the T1D manifests.Type: ApplicationFiled: May 4, 2012Publication date: May 15, 2014Applicant: DiaMedica Inc.Inventors: Mark S Willimas, Matthew L. Charles
-
Publication number: 20140127233Abstract: Methods and pharmaceutical compositions for treating severe ischemic events including cerebral infarction, cardiac infarction, or pulmonary embolism, comprising a thrombolytic intervention including thrombolytic agents and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are disclosed.Type: ApplicationFiled: January 9, 2014Publication date: May 8, 2014Applicant: NIIGATA UNIVERSITYInventors: Takayoshi SHIMOHATA, Lawrence M. KAUVAR
-
Publication number: 20140127307Abstract: The present invention relates to a small particle size composition comprising pancreatin containing digestive enzymes for use in patients in need, including pediatric, geriatric, and adult patients, particularly those patients with dysphagia or wherein enteral administration using such composition would be suitable. In addition, the invention is directed to the composition as particles, such as micropellets or microgranules having a high potency, high useable yield and at least 10%-90% of 400-800 ?m. Furthermore, the composition optionally has an improved enteric coating and concomitant improved stability and enzyme activity compared to conventional prepared enterically coated pancreatic enzyme particles.Type: ApplicationFiled: November 2, 2012Publication date: May 8, 2014Applicant: APTALIS PHARMA LIMITEDInventors: Gopi M. VENKATESH, Craig Kramer, Flavio Fabiani, Luigi Mapelli, Giovanni Ortenzi, Massimo Latino
-
Publication number: 20140127227Abstract: Provided are stable protein formulations that contain at least one amino acid. In certain embodiments, amino acid combinations either at least two, or three, or four, or more amino acids are included. By virtue of inclusion of the amino acids, the formulation has low viscosity and a protein in the formulations is physically, chemically, and biological stable even at high concentrations. In further embodiments, by virtue of inclusion of the amino acids, a protein in the formulations is physically, chemically, and biological stable even at high concentrations.Type: ApplicationFiled: October 26, 2012Publication date: May 8, 2014Inventor: Byeong Seon Chang
-
Publication number: 20140127185Abstract: Described herein are compositions and methods for treating or preventing ischemic injury. In particular, the methods and compositions relate to the use of a neuroprotective steroid, such as progesterone or allopregnanolone, and a thrombolytic agent, such as tissue plasminogen activator (tPA). Also described are compositions and methods for reducing the risks of thrombolytic agent treatment using a neuroprotective steroid.Type: ApplicationFiled: October 31, 2013Publication date: May 8, 2014Applicant: Emory UniversityInventors: Donald G. Stein, Iqbal Sayeed
-
Patent number: 8715649Abstract: Embodiments herein illustrate methods and compositions for treating medical disorders. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating graft rejection, transplant rejection or diabetes in a subject. Other embodiments herein relate to compounds including naturally occurring and synthetic mutant compositions of alpha-1 antitrypsin, wherein the alpha-1 antitrypsin has no significant serine protease inhibitor activity.Type: GrantFiled: January 30, 2009Date of Patent: May 6, 2014Inventors: Charles A. Dinarello, Eli C. Lewis
-
Publication number: 20140120151Abstract: The present invention is directed to a method for manufacturing a cross-linked gelatin sponge having a surface by providing a cross-linked gelatin sponge, wetting the surface of the sponge by applying a sufficient amount of liquid comprising a protein or peptide active ingredient, wherein a sufficient amount of liquid is one that retains the flexibility of the sponge even after drying. The sponge is then dried the sponge to obtain a flexible, dry and ready to use cross linked gelatin sponge having a layer of protein or peptide active ingredient on the surface thereof.Type: ApplicationFiled: March 20, 2013Publication date: May 1, 2014Inventors: Israel Nur, Liliana Bar, Guy Tomer, Eyal Sheetrit
-
Publication number: 20140120078Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: ApplicationFiled: December 9, 2013Publication date: May 1, 2014Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa
-
Publication number: 20140120155Abstract: Factor Xa variants and methods of use thereof are disclosed.Type: ApplicationFiled: December 23, 2012Publication date: May 1, 2014Applicant: THE CHILDREN'S HOSPITAL OF PHILADELPHIAInventor: The Children's Hospital of Philadelphia
-
Patent number: 8697118Abstract: A hemostatic product that includes a dextran support, at least one hemostatic agent and at least one hemostatic agent stabilizer. The at least one hemostatic agent is selected from the group consisting of thrombin and fibrinogen. The at least one hemostatic agent is associated with the dextran support. The at least one hemostatic agent stabilizer is associated with the at least one hemostatic agent.Type: GrantFiled: September 19, 2012Date of Patent: April 15, 2014Assignee: St. Teresa Medical, Inc.Inventors: Curtis E. Olson, Philip A. Messina
-
Publication number: 20140093491Abstract: The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of Gal?1,3G al glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII.Type: ApplicationFiled: May 2, 2013Publication date: April 3, 2014Applicant: LFB BIOTECHNOLOGIESInventor: LFB BIOTECHNOLOGIES
-
Publication number: 20140086897Abstract: Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin.Type: ApplicationFiled: April 18, 2013Publication date: March 27, 2014Applicant: MOREHOUSE SCHOOL OF MEDICINEInventor: Byron D. FORD
-
Publication number: 20140086898Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: ApplicationFiled: August 19, 2013Publication date: March 27, 2014Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian
-
Publication number: 20140086899Abstract: The present disclosure relates generally to the field of diagnostic and prognostic assays for a condition or event of a vascular system such as the cerebrovascular system. An assay is taught herein for monitoring progression of a condition or event of a vascular system such as the cerebrovascular system as well as determining the state or stage of the condition or event. The assay of the present disclosure is also useful in the stratification of a subject based on the stage or development of the condition or event.Type: ApplicationFiled: January 27, 2012Publication date: March 27, 2014Applicant: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONInventors: David William Howells, William John Wilson
-
Publication number: 20140086872Abstract: Methods are provided for treating a subject for at least one condition that includes inflammation, a blood clotting condition and autonomic nervous system dysfunction such as adrenergia, e.g., simultaneously. Also provided are kits for use in practicing the subject methods.Type: ApplicationFiled: September 24, 2013Publication date: March 27, 2014Applicant: PALO ALTO INVESTORSInventors: Anthony Joonkyoo Yun, Patrick Yuarn-Bor Lee
-
Patent number: 8679482Abstract: The present invention relates to the use of plasminogen and plasmin as agents for enhancing healing of tympanic membrane perforations or other wounds, and for reducing scars or necrotic tissue forming during wound healing. The invention also relates to a method for screening of compounds which enhance wound healing by evaluating the healing of tympanic membrane perforations in an animal model.Type: GrantFiled: November 30, 2007Date of Patent: March 25, 2014Assignee: Omnio Healer ABInventors: Tor Ny, Jinan Li, Sten Hellstrom, Per-Olof Eriksson
-
Publication number: 20140079685Abstract: A method and composition for treating serotonin receptor-mediated conditions.Type: ApplicationFiled: November 25, 2013Publication date: March 20, 2014Applicant: Vanda Pharmaceuticals Inc.Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt Wolfgang
-
Publication number: 20140079684Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Type: ApplicationFiled: June 11, 2013Publication date: March 20, 2014Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
-
Patent number: 8673361Abstract: The invention relates to an agent having cytokine mediating activity. In particular the invention relates to a composition comprising a fraction of denatured plasma proteins and at least one metal, metal ion or metal salt thereof, wherein said mixture has cytokine mediating activity.Type: GrantFiled: April 27, 2007Date of Patent: March 18, 2014Assignee: Cambridge Scientific Pty LtdInventor: Maud Louisa Johanna Maria Eijkenboom